Compare AVLN & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | HLF |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 2004 |
| Metric | AVLN | HLF |
|---|---|---|
| Price | $28.73 | $12.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 258.9K | ★ 1.3M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $5,037,500,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $3.80 |
| P/E Ratio | ★ N/A | $21.89 |
| Revenue Growth | N/A | ★ 0.89 |
| 52 Week Low | $24.90 | $7.56 |
| 52 Week High | $33.32 | $20.40 |
| Indicator | AVLN | HLF |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 47.77 |
| Support Level | $26.68 | $11.47 |
| Resistance Level | $29.59 | $12.82 |
| Average True Range (ATR) | 1.99 | 0.44 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 61.44 | 39.15 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.